OmniAb, Inc. (OABI)
OmniAb, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in EmeryVille, CA, US. The stock last traded at $3.38, up 0.00% on the session, giving a market capitalisation of $490.0M. On trailing twelve-month figures it carries a trailing P/E of -9.39, a net margin of -115.2%. Its beta of 1.22 implies it has historically moved more than the broad market.
OmniAb, Inc. is an American biotechnology firm focused on pioneering therapeutic antibody discovery. The company provides a sophisticated platform that allows its industry partners to access a broad spectrum of antibody repertoires and advanced screening techniques, thereby facilitating the development of next-generation treatments. Central to the OmniAb platform is the unique biological capability of proprietary genetically engineered animals, such as OmniRat, OmniChicken, and OmniMouse. These animals are modified to produce human-sequence antibodies, simplifying the creation of human therapeutic candidates. Additionally, OmniAb offers specialized technologies like OmniFlic (a transgenic rat) and OmniClic (a transgenic chicken), which address the requirements for bispecific antibody applications via a common light chain method, as well as OmniTaur, which leverages the distinct structural properties of cow antibodies for challenging targets. The company was founded in 2012 and is based in Emeryville, California.
OmniAb, Inc. is most often compared with the following Healthcare names: